MPC-9528 is an orally-bioavailable, small molecule Cancer Metabolism Inhibitor (CMI) discovered by Myrexis that is currently in preclinical development for the treatment of a variety of cancers. MPC-9528 potently and selectively inhibits nicotinamide phosphoribosyltransferase, or Nampt, an enzyme critical for converting nicotinamide into nicotinamide adenine dinucleotide (NAD). Cellular processes such as glucose metabolism, DNA repair and gene expression require and consume NAD. Cancer cells have increased NAD requirements and are highly sensitive to NAD depletion. Blocking the Nampt-NAD pathway severely inhibits cancer cell metabolism, resulting in energy deprivation and ultimately cell death. In animal models, MPC-9528 causes dramatic tumor regressions across multiple tumor types.
Normal healthy human cells produce NAD by a number of different pathways. Additional research however, indicates that that many cancers, as much as 40% of all cancers, lose the ability to produce NAD by these alternative pathways and become absolutely dependent upon Nampt activity. Patients with these tumor types would be particularly responsive to MPC-9528 therapy and a simple companion diagnostic may be used to identify these patients. MPC-9528 has the potential to be the best-in-class Nampt inhibitor with promise for treating a wide variety of cancers.
About Myrexis, Inc.Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and preclinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomic drug discovery and clinical and commercial development. For more information, please visit www.myrexis.com . The Myrexis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6327. Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries.